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Aims In this study, we wished to determine whether angiopoietin-1 (Ang1) modiﬁed the permeability
coefﬁcients of non-inﬂamed, intact continuous, and fenestrated microvessels in vivo and to elucidate
the underlying cellular mechanisms.
Methods and results Permeability coefﬁcients were measured using the Landis–Michel technique (in
frog and rat mesenteric microvessels) and an oncopressive permeability technique (in glomeruli).
Ang1 decreased water permeability (LP: hydraulic conductivity) in continuous and fenestrated microves-
sels and increased the retention of albumin (s: reﬂection coefﬁcient) in continuous microvessels. Endo-
thelial glycocalyx is common to these anatomically distinct microvascular beds, and contributes to the
magnitude of both LP and s. Ang1 treatment increased the depth of endothelial glycocalyx in intact
microvessels and increased the content of glycosaminoglycan of cultured microvascular endothelial
cell supernatant. Ang1 also prevented the pronase-induced increase in LP (attributable to selective
removal of endothelial glycocalyx by pronase) by restoration of glycocalyx at the endothelial cell
surface. The reduction in permeability was inhibited by a cell transport inhibitor, Brefeldin.
Conclusion Ang1 modiﬁes basal microvessel permeability coefﬁcients, in keeping with previous reports
demonstrating reduced solute ﬂux in inﬂamed vessels. Anatomical, biochemical, and physiological evi-
dence indicates that modiﬁcation of endothelial glycocalyx is a novel mechanism of action of Ang1 that
contributes to these effects.
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1. Introduction
Ang1 is a 70-kDa glycoprotein that shares homology with a
number of other angiopoietins and angiopoietin-like mol-
ecules.
1 Their expression and activity have been demon-
strated across a range of vertebrate families encompassing
mammals
2,3 and amphibians.
4 Ang1 is a ligand for the tyro-
sine kinase receptor Tie2, expressed by endothelial cells
throughout the vasculature,
1 and a small number of other
cell types.
5 Ang1 is constitutively expressed and its receptor,
Tie2, is constitutively phosphorylated in many adult tissues.
3
Endothelial cell responses to Ang1 in vitro include
chemotaxis, prevention of apoptosis, sprouting, and tube
formation.
1 Activities in vivo include reduction of leukocyte
adhesion and other markers of inﬂammation,
6 and tissue-
speciﬁc and time-speciﬁc alterations in angiogenesis.
7,8
The primary function of the microvasculature is to regu-
late exchange of substances between plasma and abluminal
compartments (e.g. interstitium, or urinary space in the
case of glomeruli). The mass of solute and solvent crossing
microvascular walls is determined by
(i) the forces acting across microvessel walls that drive
solute/solvent ﬂux (net hydrostatic and oncotic
pressure gradients, concentration gradients),
(ii) haemodynamic forces (plasma ﬂow rate, area avail-
able for exchange), and
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Microvascular permeability [point (iii)] is described by
three permeability coefﬁcients: hydraulic conductivity (LP:
the ease with which water crosses microvessel walls), reﬂec-
tion coefﬁcient (s: the fraction of a solute that cannot be
dragged across microvessel walls with the convective ﬂux
of solvent), and the diffusive solute permeability coefﬁcient
(PS: the degree to which microvessel walls hinder the diffu-
sive movement of solute from lumen to abluminal
compartment).
All previous studies that have attempted to investigate the
effectofAng1onmicrovascularpermeability inintactvessels
have measured solute (or solvent) ﬂux (determined by all
three factors listed above), rather than measuring microvas-
cularpermeability(i.e.permeabilitycoefﬁcients)perse.The
Miles Assay,
9 leak of ﬂuorescent microspheres
10 and paw
oedema
11 are all measures of the composite parameters of
solute/solvent ﬂux, rather than speciﬁc measures of the con-
tribution of microvessel permeability coefﬁcients to solute
ﬂux. Because Ang1 affects arteriolar resistance,
12 changes
in hydrostatic pressure gradients, area available for
exchange, plasma ﬂow rate, and consequently concentration
gradients are all likely to occur in response to Ang1.
13 These
studies are limited in their ability to reveal the mechanisms
by which Ang1 alters total solute ﬂux in intact vessels
in vivo, particularly under the baseline conditions under
which the Ang1–Tie2 axis is active.
3 Ang1 would be predicted
to alter solute ﬂux by modulating the contribution of the
endothelium to microvascular permeability, given the
effects of this ligand on endothelial cell biology, and tech-
niques that can discriminate changes in permeability coefﬁ-
cients from changes in haemodynamic forces and driving
forces are necessary to demonstrate the contribution of
altered permeability coefﬁcients.
Evidence that Ang1 modiﬁes permeability coefﬁcients has
been provided by in vitro studies, in which application of
Ang1 to endothelial cell monolayers reduces both water
and albumin ﬂux,
14,15 predominantly via alteration of the
activity and expression of molecules involved in the integrity
of inter-endothelial cell junctions, such as VE-cadherin,
PECAM-1, and b-catenin.
14 It is critical to note, however,
that the permeability coefﬁcients of endothelial cell mono-
layers are both quantitatively and qualitatively different
from those of intact microvessels in vivo: indeed, the per-
meability coefﬁcients of endothelial cell monolayers are
comparable to those of inﬂamed microvessels.
16 Ang1 has
a multiplicity of anti-inﬂammatory actions, and all of the
aforementioned studies of solute–solvent ﬂux in vivo have
examined the effects of Ang1 following an inﬂammatory
stimulus. Ang1, however, is typically expressed under base-
line (i.e. non-inﬂamed) conditions, and the effects of Ang1
on microvascular permeability and/or solute–solvent ﬂux
have not been examined under these baseline, non-inﬂamed
conditions.
We therefore sought to examine whether Ang1 modiﬁes
microvascular permeability coefﬁcients under conditions in
which all other determinants of transvascular solute and
solvent movement are known and controlled, and to deter-
mine these inﬂuences in the resting state, i.e. without prior
induction of inﬂammation.
We also sought to compare the effects of Ang1 on the
hydraulic conductivity of microvessels with continuous and
fenestrated endothelia. Paracellular routes (i.e. through
the inter-endothelial cleft) dominate ﬂuid ﬂux in continuous
capillaries,
17 but transcellular routes (i.e. through the
fenestrations) dominate ﬂuid ﬂux in fenestrated capil-
laries.
18 If Ang1 modiﬁes permeability coefﬁcients in intact
microvessels via modiﬁcation of inter-endothelial cleft mol-
ecules, then changes in continuous microvessel water per-
meability (LP), but not fenestrated microvessel LP, would
be expected in response to Ang1.
2. Methods
2.1 Animal preparation
Experiments on adult frogs (Rana temporaria) and rats (Wistar)
were performed in accordance with both the Guide for the Care
and Use of Laboratory Animals published by the US National Insti-
tutes of Health and UK Home Ofﬁce legislation. Mesenteric per-
meability experiments were performed as described by Bates and
coworkers,
19 and glomerular permeability experiments as reported
by Salmon et al.
20 (see Supplementary material online).
2.2 Systemic microvessel permeability coefﬁcient
measurement
In view of the difﬁculties in separating permeability coefﬁcients
using more widely used methodologies, we used the Landis–Michel
micro-occlusion technique, as we have previously described in
intact microvessels in vivo
19 (see Supplementary material online
for details). This technique allows the precise measurement of per-
meability characteristics, as the intravascular forces that determine
transvascular ﬂuid and solute ﬂux (hydrostatic and oncotic press-
ures) are controlled. Individual microvessels (16–37 mm; capillaries
and post-capillary venules) of known surface area in the mesentery
were cannulated with a bevelled micropipette, while the mesentery
was superfused with Ringer’s solution. The vessels were then per-
fused with bovine serum albumin (BSA) at a known concentration,
and erythrocytes (as ﬂow markers), at a deﬁned pressure. To
measure LP and s, vessels were occluded with a ﬁne glass rod.
Fluid ﬁltration rate per unit area was calculated from the rate of
erythrocyte movement and the cross-sectional area of the vessel.
LP ( 10
27 cm s
21 cm H2O
21) was calculated from the slope of the
relationship between ﬁltration rate and applied pressure, and s
from the abscissal intercept.
Permeability coefﬁcients were measured before and after micro-
vessel perfusion with recombinant human Ang1 (R&D Systems;
200 ng mL
21) or vehicle (1  phosphate-buffered saline). In separate
experiments on frog microvessels, the ability of Ang1 to inhibit the
pronase-induced increase in LP that has previously been reported in
the same system
21 was assessed by measuring LP during pre-
perfusion of the microvessel with either Ang1 or vehicle solution
for 30 min, followed by LP measurement after brief and transient
(,90 s) microvessel perfusion with 0.1 mg mL
21 pronase, following
which the initial perfusate (Ang1 or BSA) was restored (please see
Supplementary material online for details). LP was also measured
in vessels that were only perfused with Ang1 following pronase
exposure. To examine whether Ang1 inhibits the translocation of
pre-formed glycocalyx constituents from intracellular stores, frog
microvessels were co-perfused with Ang1 (200 ng mL
21) and the
Golgi vesicle translocation inhibitor 100 mm Brefeldin-A.
22
2.3 Electron microscopy
Frog microvessels were perfused initially with BSA-Ringer containing
Ang1 or vehicle, with or without subsequent pronase exposure, as
for permeability studies. Thereafter, perfusion with albumin-free
Ringer solution for 1 min, then Alcian Blue solution for 5 min, was
instituted. Vessels were then ﬁxed by ﬂooding the mesentery with
4% ice-cold gluteraldehyde in cacodylate buffer. After ﬁxation,
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mesentery was cut away from the animal, stored in cacodylate-
buffered 4% gluteraldehyde at 48C overnight, post-ﬁxed in 1%
osmium tetroxide, and embedded in araldite blocks using standard
techniques. The perfused microvessel was identiﬁed in the block,
and transverse ultrathin (100 nm) sections were prepared. The sec-
tions were stained with lead citrate and uranyl acetate before being
viewed in a Phillips 100CS electron microscope. Images were pre-
pared from between two and four vessels per treatment group
(mean: 3.25 vessels).
Electron microscopy (EM) images of microvessels were analysed
with Adobe Photoshop (R). A calibrated electronic grid was applied
to EM images and (i) glycocalyx depth (luminal edge of plasmalemma
to luminal edge of glycocalyx); (ii) glycocalyx separation from the
plasmalemma (luminal edge of plasmalemma to the nearest detect-
able glycocalyx); and (iii) inter-endothelial cleft width (wide cleft
regions only) were measured at regular 50 nm intervals. In addition,
the number of tight junctions (electron dense, narrow, regions of
inter-endothelial clefts) were recorded for each treatment group,
and divided into the total cleft length for each treatment group,
to reveal the mean cleft length per tight junction.
2.4 Glomerular permeability coefﬁcient
measurement
Glomeruli were isolated from rat kidneys using a standard sieving
technique,
20 and treated with Ang1 or vehicle for 60 min in a
blinded fashion. Individual glomeruli were loaded onto the tip of
an aspiration micropipette within a ﬂow-controlled glass obser-
vation chamber, and glomerular proﬁle recorded during exchange
of surrounding solution from 10 to 80 mg mL
21 BSA. The consequent
rate of glomerular volume reduction (which represents the rate of
ﬂux of ﬂuid from glomerular capillary lumina across the glomerular
ﬁltration barrier: JV) was analysed off-line. Glomerular hydraulic
conductivity–surface area product (LPA) was calculated from the
quotient of rate of volume change and applied oncotic pressure:
LPA ¼
JV
 Dp
ðnLmin
 1 mmHg
 1Þð 1Þ
2.5 Endothelial cell glycosaminoglycan assay
in vitro
Adult dermal human microvascular endothelial cells (Cambrex)
were grown to 60–70% conﬂuency, serum-starved for 24 h and
then exposed to Ang1 or vehicle for 48 h. Supernatant was then aspi-
rated, centrifuged, incubated with papain (to eliminate interfer-
ence from proteins and glycoproteins
23,24) and added to an Alcian
Blue solution. The linear relation between mass of glycosaminogly-
can and the degree of reduction in 488 nm light absorption by Alcian
Blue solution
25 was used to quantify supernatant glycosaminoglycan
content.
2.6 Statistics
Mesenteric microvessel LP values are not normally distributed:
26
results are reported as median+semi-interquartile range, and ana-
lysed with non-parametric statistics. All other results are reported
as mean+SEM, and compared with parametric statistics. For per-
meability coefﬁcient experiments, numerical results and associated
statistical evaluations are given in Table 1.
3. Results
3.1 Angiopoietin-1 reduces LP of vessels with
continuous endothelium
While LP was unaltered by BSA perfusion, luminal perfusion
with 200 ng mL
21 Ang1 caused a signiﬁcant reduction in LP
of frog microvessels. The reduction in LP was complete
after 20 min, and no further reductions in LP were observed
during the following 40 min of perfusion with Ang1
(Figure 1A and B). Identical effects were observed in a mam-
malian system (rat mesenteric microvessels: Figure 1C and
D). There was no relation between the magnitude of fall in
LP and baseline LP (Figure 1E). The effect of Ang1 on LP was
reversible, in that LP returned to baseline levels 30 min after
removal of Ang1 from the perfusate (Figure 1, Supplemen-
tary material online).
3.2 Angiopoietin-1 increases s of vessels with
continuous endothelium
Measurement of ﬁltration rate under increasing pressure in
the vessel (Figure 2) was performed in 10 vessels. The
slope of the relation between Jv and Pc (i.e. the hydraulic
conductivity, LP) was (again) signiﬁcantly reduced by Ang1.
The abscissal intercept of the relation between Jv and Pc
[i.e. the mean effective oncotic pressure (sDp) difference
across the vessel wall] was signiﬁcantly elevated by Ang1:
this corresponds to an increase in albumin reﬂection coefﬁ-
cient (salb, i.e. a decrease in macromolecular permeability)
from 0.78+0.03 to 0.91+0.03 (n ¼ 10 pairs; P , 0.001,
paired t-test). This effect was observed in all the 10
vessels studied (Figure 2), and was observed even in
vessels with the highest baseline values of sDp. As for LP,
s returned to baseline values 30 min after removal of Ang1
from the perfusate (Figure 1, Supplementary material
online).
3.3 Angiopoietin-1 reduces LPA of vessels with
fenestrated endothelium
Treatment with 200 ng mL
21 Ang1 reduced the hydraulic
conductivity of fenestrated rat glomerular capillaries to
76% of control, assuming no change in glomerular vascular
area during the measurement (Figure 3). Ang1 was therefore
able to reduce vascular permeability to water both in vessels
with continuous and fenestrated endothelium.
We therefore investigated the possibility that Ang1
modiﬁed a structure that is present in both continuous and
fenestrated microvessels, and contributes to hydraulic
resistance and macromolecular sieving properties in both
the vessel types: the endothelial glycocalyx.
3.4 Angiopoietin-1 prevents the pronase-induced
increase in LP in vivo
Using the Landis–Michel technique, Adamson showed that
brief perfusion of frog mesenteric microvessels with
pronase caused both selective removal of the endothelial
glycocalyx (but leaves the underlying endothelial cells
intact) and a 2.5-fold increase in LP.
21 We have used the
same protocol in the same animal species to examine
whether Ang1 modiﬁes permeability coefﬁcients by modify-
ing endothelial glycocalyx.
Transient perfusion of vessels with pronase caused a 2.6+
0.4-fold increase in LP over baseline (n ¼ 9). This
pronase-induced increase in LP was attenuated to 1.2+
0.3-fold in vessels pre-perfused with Ang1 for 30 min (n ¼
6; P , 0.05, unpaired t-test; Figure 3C). Perfusing vessels
with Ang1 for 30–45 min after exposure to pronase also atte-
nuated the pronase-induced LP increase, when compared
A.H.J. Salmon et al. 26with pronase treatment alone (pronase alone: 3.6+1.1-fold
increase in LP over baseline (n ¼ 4); pronase followed by
Ang1: 1.5+0.2-fold increase in LP over baseline (n ¼ 5;
P , 0.05, Mann–Whitney U test; Figure 3D).
3.5 Angiopoietin-1 modiﬁes endothelial glycocalyx
To visualize whether Ang1 modiﬁed the glycocalyx, the gly-
cocalyx was stained in perfused vessels with Alcian Blue, and
processed and examined by electron microscopy (Figure 4).
Perfusion with Alcian Blue resulted in the staining of a 50–
100 nm thick glycocalyx attached to, but above the plasma-
lemma (Figure 4A). Perfusion with Ang1 resulted in a thicker
layer, which upon higher power examination could be seen
to be a diffuse glycocalyx (Figure 4B) still attached to the
plasmalemma. Treatment with pronase resulted in a
darker stained glycocalyx (Figure 4C), which was clearly
separated from the plasmalemma (arrows, Figure 4C). Sub-
sequent treatment with Ang1 restored direct contact
between glycocalyx and plasmalemma (Figure 4D).
To quantify changes, the depth of endothelial glycocalyx
in microvessels perfused with BSA alone, as determined
with Alcian Blue staining and electron microscopic analysis,
was measured. In control, the glycocalyx was 44.5+3.6 nm
(n ¼ 96 measurements; n ¼ 6 images, Figure 5A); glycocalyx
depth in vessels perfused with Ang1 for 30 min was 87.1+
3.2 nm (n ¼ 171 measurements; n ¼ 6 images; P , 0.05,
unpaired t-test; Figure 5A). Pronase exposure reduced the
Figure 1 Angiopoietin-1 decreases continuous microvessel hydraulic conductivity (LP). LP was measured by cannulation and perfusion of individual mesenteric
microvessels, and determination of transcapillary ﬂuid ﬂux under known hydrostatic capillary pressures. (A) Perfusion of 11 frog microvessels with 200 ng mL
21
Angiopoietin-1 (Ang1; closed symbols) caused a steady and sustained decrease in LP compared with 1% bovine serum albumin (BSA) alone (vehicle; open symbols)
(*P , 0.05 vs. baseline, one-way analysis of variance for all subsequent timepoints). (B) Seventy minute-perfusion of frog mesenteric microvessels with BSA alone
(vehicle; open circles; squares+error bars represent median+semi-IQR) caused no signiﬁcant change in LP (
nsP . 0.60, n ¼ 10 pairs). In contrast, 70-min per-
fusion with BSA supplemented with 200 ng mL
21 Ang1 (ﬁlled circles) reduced LP in 10 of 11 vessels studied (*P , 0.05, Wilcoxon, n ¼ 11 pairs). (C) As for frog
vessels, Ang1 induced a signiﬁcant reduction in rat mesenteric microvessel LP after 15 min exposure. This reduction again persisted for the remaining 45 min
of perfusion (*P , 0.05 vs. baseline, one-way ANOVA for all subsequent timepoints). (D) Perfusion with 200 ng mL
21 rhAng1 caused a reduction in LP in all six
rat mesenteric microvessels studied (*P , 0.05, Wilcoxon; squares+error bars represent mean+SEM). (E) There was no relation between baseline LP and
the magnitude of fall in LP induced by Ang1 (Spearman r ¼ 0.16; P . 0.4; n ¼ 28 frog vessels).
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ments, n ¼ 20 images; control: 44.5+3.6 nm; P , 0.05,
one-way analysis of variance (ANOVA), Bonferroni]. In
addition, pronase treatment elicited a signiﬁcant separation
of the glycocalyx from the underlying endothelial cell
plasma membrane that was not evident under baseline con-
ditions (6.9+0.4 nm; Figure 5B; n ¼ 104 measurements,
n ¼ 20 images). Ang1 treatment replenished this
pronase-induced gap, immediately adjacent to the plasma-
lemma, with glycocalyx (separation 2.5+0.4 nm; n ¼ 66
measurements, n ¼ 14 images; P , 0.05 vs. pronase alone,
one-way ANOVA, Bonferroni, Figure 5B). However, total
depth of glycocalyx was not preserved by Ang1 pre-
treatment (21.4+0.9 nm (n ¼ 66 measurements, n ¼ 14
images; not signiﬁcantly different from pronase alone: P .
0.05, one-way ANOVA, Bonferroni). There was no difference
in inter-endothelial cleft width between control [21.1+
1.6 nm (n ¼ 6)] and Ang1 [20.6+1.8 nm (n ¼ 9)]-treated
vessels (P . 0.8, unpaired t-test, Figure 5C). In addition,
cleft lengths (control: 306 nm; Ang1: 299 nm) were
similar in control and Ang1-treated vessels and the fre-
quency of tight junctions within inter-endothelial clefts
(approximately one per cleft for each group) was also the
same resulting in no difference between tight junction
interval along the cleft (Figure 5D). There were also no
signiﬁcant differences in inter-endothelial cleft width
(pronase: 21.3+0.59 nm; pronaseþAng1: 20.9+0.4 nm;
P . 0.05, one-way ANOVA, Bonferroni), inter-endothelial
cleft length (pronase: 356+46.0 nm; pronaseþAng1:
470+111 nm; P . 0.35, unpaired t-test), or tight junction
frequency [pronase: 1.2 tight junctions per cleft (n ¼ 6);
pronaseþAng1: 1.6 tight junctions per cleft (n ¼ 7);
P . ;0.45, unpaired t-test)], between pronase-treated
and Ang1þpronase-treated vessels, nor between any of
the treatment groups and baseline conditions (Figure 5C
and D).
3.6 Angiopoietin-1 modiﬁes endothelial cell
glycosaminoglycan turnover, inhibition of which
blocks the Ang1 reduction in LP
To determine whether Ang1 could affect the rate of endo-
thelial glycocalyx turnover, endothelial cells in culture
were treated with Ang1 in vitro. This increased the mass
of glycosaminoglycan constituents in the supernatant of
endothelial cells (e.g. heparan sulphate) from 6.2+0.8 mg
to 12.5+1.1 mg( P , 0.05, unpaired t-test; Figure 5E). Gly-
cocalyx is inserted onto the cell surface by vesicle fusion
regulated by Golgi-mediated translocation. To determine
whether this was required for the Ang1 effect in vivo,
Figure 2 Angiopoietin-1 increases continuous microvessel reﬂection coefﬁcient (s). (A) A single frog mesenteric capillary perfused with 3% bovine serum
albumin (BSA), submitted to a series of vessel occlusions made at a variety of luminal hydrostatic pressures (Pc) under baseline conditions (vehicle; open
circles), and subsequently following 30-min perfusion with 200 ng mL
21 Angiopoietin-1 (Ang1; closed circles). LP, the slope of the relation between ﬂuid ﬂux
rate per unit vessel area (Jv/A) and Pc was reduced by Ang1, and the x-axis intercept of this relation [triangle: effective oncotic pressure difference (sDp)]
was increased. (B) sDp was unaltered by 30-min perfusion with vehicle (BSA alone: open circles; squares+error bars represent mean+SEM; n ¼ 5 pairs;
nsP . 0.9, paired t-test). (C) In contrast, 30-min treatment with Ang1 increased sDp (and hence s) in all the 10 vessels studied (*P , 0.001, paired t-test)
(squares+error bars represent mean+SEM).
A.H.J. Salmon et al. 28vessels were perfused with the Golgi vesicle translocation
inhibitor brefeldin-A (100 mM) before treatment with Ang1.
The reduction in baseline LP observed in response to Ang1
(Figure 1) was blocked by co-perfusing vessels with
Ang1 (200 ng mL
21) and brefeldin A [Ang1 alone signiﬁcantly
lower than both control (P , 0.05) and Ang1þbrefeldin-A
(P , 0.05); brefeldin-A not signiﬁcantly different from
control (P . 0.05; all one-way ANOVA, Figure 5F)].
4. Discussion
We show here that perfusion of microvessels with continuous
endothelium with Ang1 in vivo lowers baseline LP and
increases reﬂection of albumin by the microvessel wall.
This was demonstrated in non-inﬂamed vessels, in which
LP and s are the same as values previously reported for non-
inﬂamed vessels in frogs
27 and rats.
28 The majority of
reports demonstrating reduced transvascular solute move-
ment following Ang1 treatment in vivo, or in intact organ
preparations ex vivo, have either examined the effect of
Ang1 following application of a stimulus (e.g. mustard oil
29
or bradykinin
10) or in animal models of disease (e.g. diabetic
retinopathy
6). Reduced solute movement may be related to:
a change in the permeability coefﬁcients of vessel walls
(such as LP and s); the extent of microvascular network per-
fusion;
30 the net driving forces for solute movement (e.g.
reduced hydrostatic pressure resulting from vasoconstric-
tion); a combination of these factors; or to a number of
other factors.
13 The aforementioned studies did not dis-
criminate between these factors. The results presented in
this study are consistent with these reports, but show that
one physiological mechanism for those observations is a
direct effect of Ang1 on the permeability coefﬁcients of
microvascular walls.
We also show that Ang1 reduced the hydraulic conduc-
tivity–surface area product of the fenestrated glomerular
capillary network, in agreement with reports of increased
transendothelial electrical resistance (a marker of water
and small solute permeability) across glomerular endothelial
cell monolayers following Ang1 treatment.
15 These obser-
vations together highlight three actions of Ang1 on micro-
vascular permeability coefﬁcients: reduced LP of
continuous microvessels; increased albumin reﬂection by
continuous microvessels; and reduced LPA of fenestrated
microvessels. The pathways that regulate these per-
meability coefﬁcients have distinct components, and this
diversity can provide insight into the cellular mechanisms
underlying the Ang1 effect.
Figure 3 Angiopoietin-1 decreases glomerular water permeability and attenuates the pronase-induced increase in hydraulic conductivity (LP). Baseline glomer-
ular volume was measured after 60 min exposure to 200 ng mL
21 Ang1 (n ¼ 30) or vehicle (n ¼ 31) in low oncotic pressure solution, and again immediately after
exchange to high oncotic pressure solution (that induced ﬂuid efﬂux from glomeruli). (A) The slope of the mean glomerular volume–time relation was signiﬁ-
cantly shallower for angiopoietin-1-treated glomeruli (*P , 0.05, one-way analysis of variance). (B) This reduction in the rate of ﬂuid movement across the glo-
merular ﬁltration barrier equates to a 24% reduction in glomerular LPA (*P , 0.05, unpaired t-test). (C) Ang1 pre-treatment prevented the pronase-induced
increase in LP (*P , 0.05, unpaired t-test) in frog mesenteric microvessels. (D) LP remained elevated 30–45 min after initial exposure to pronase [LP 3.6+
1.1-fold higher than baseline (n ¼ 4)]. LP values were restored towards baseline levels in pronase-exposed vessels subsequently perfused with 200 ng mL
21
rhAng1 (LP 1.5+0.2-fold higher than baseline (n ¼ 5; *P , 0.05 vs. pronase alone-treated vessels, Mann–Whitney U test).
Ang1 alters glycocalyx and permeability coefﬁcients 29The frequency of breaks in the tight junction strands in
inter-endothelial clefts are a critical determinant of the LP
of continuous microvessels. Substances that increase the
number of tight junction strands present in inter-endothelial
clefts (e.g. cAMP analogues) reduce baseline LP.
31 Ang1 mod-
iﬁes a number of inter-endothelial cleft molecules, e.g.
occludin, PECAM-1, b-catenin, and VE-cadherin.
14,32 These
tight-junction strand breaks, however, are not signiﬁcant
regulators of the reﬂection coefﬁcient of the vessel wall,
31
and changes in inter-endothelial clefts are therefore unli-
kely to explain the increase in s observed following appli-
cation of Ang1. The cellular structure that correlates to
the ‘large pore’ that governs the magnitude of s remains
controversial: both trans-endothelial (vesiculo-vacuolar
organelles, caveolae), and inter-endothelial pathways have
been postulated.
17 Furthermore, reduced LPA in response
to Ang1 in the fenestrated glomerular capillary network is
unlikely to represent alterations in hydraulic inter-
endothelial pathways. The vast majority of ﬂuid ﬂux across
the glomerular endothelial cell layer is via fenestrae,
rather than inter-endothelial clefts,
33 such that it seems
highly unlikely that Ang1 reduces glomerular LPA by altering
the clefts between glomerular endothelial cells.
It is conceivable that the plethora of observed actions of
Ang1 on permeability coefﬁcients are mediated by modiﬁ-
cation of a variety of different ultrastructural features of
different microvascular beds that result in parallel changes
in permeability coefﬁcients. An alternative explanation is
that Ang1 modiﬁes a structure that is common to both con-
tinuous and fenestrated capillaries, and that contributes to
both hydraulic conductivity and molecular sieving of micro-
vessel walls. The endothelial glycocalyx appears to be a
good candidate for this. The ﬁbre–matrix junction break
model, originally outlined by Curry and Michel in 1980,
34
proposes that the size, orientation and spacing of the
ﬁbres that form the endothelial glycocalyx layer on the
luminal aspect of endothelial cells contribute to the resist-
ance to water ﬂow and molecular selectivity of the vessel
wall. Endothelial glycocalyx lies across the surface of both
inter-endothelial clefts in vessels with continuous endo-
thelium
21 and across fenestrae in glomerular capillaries,
35
and endothelial glycocalyx has been shown to contribute
to hydraulic resistance and molecular sieving in vessels
with continuous endothelia
21,36 and vessels with fenestrated
endothelia.
37,38 Modiﬁcation of a number of features of gly-
cocalyx by Ang1, such as depth and/or density, would be
Figure 4 Angiopoietin-1 modiﬁes endothelial glycocalyx in vivo. Electron micrographs of frog mesenteric microvessels following perfusion with (A) bovine serum
albumin (BSA) alone, (B) Ang1, (C) pronase, and (D) Ang1 before and after pronase. Following perfusion with experimental agents, microvessels were treated
with Alcian Blue (to stain endothelial glycocalyx), ﬁxed with glutaraldehyde, and prepared for electron microscopy. Endothelial glycocalyx was signiﬁcantly
deeper following Ang1 treatment (B). Glycocalyx was shallower and more electron dense after exposure to pronase, and was separated from the plasmalemma
(double arrow head) (C). Near-continuity between glycocalyx and plasmalemma, but not glycocalyx depth, was restored by Ang1 treatment of pronase-exposed
vessels (D). ESL, endothelial surface layer; L, lumen; G, glycocalyx; P, plasmalemma; EC, endothelial cell; V, vesicle; I, interstitium.
A.H.J. Salmon et al. 30expected to increase the hydraulic resistance (i.e. decrease
LP or LPA) and to increase reﬂection of large solutes (i.e.
increase s).
17 Ang1-induced changes in microvascular glyco-
calyx depth, and endothelial cell supernatant glycosamino-
glycan content, support the contention that Ang1 modiﬁes
endothelial glycocalyx.
We have shown an increase in the depth of glycocalyx
lining microvascular endothelial cells following perfusion
with Ang1 for 30 min in vivo. The ultrastructural changes
described here induced by Ang1 would be predicted to
alter microvascular permeability characteristics (given the
contribution that endothelial glycocalyx makes to the mag-
nitude of permeability coefﬁcients
21,36,37), but these obser-
vations do not by themselves demonstrate that the
Ang1-induced change in permeability coefﬁcients is
mediated by an alteration in endothelial glycocalyx.
However, taken together with the loss of the Ang1-induced
reduction in LP by inhibition of the Golgi vesicle
translocation system upon which translocation of glycosami-
noglycans to the cell surface depends;
22,39 both abrogation
and accelerated recovery from the rise in LP that accompa-
nies removal of the endothelial glycocalyx in vivo and that
the prevention of pronase-induced increased LP was
accompanied by restoration of near-continuity between
the glycocalyx and the endothelial plasmalemma when the
microvessels were pre-treated with Ang1, these ﬁndings
strongly implicate the glycocalyx as being a key mechanism
through which Ang1 exerts its permeability effects. Extra-
cellular matrix modulates the activity and availability of
endothelial cell survival factor pathways:
40 our observations
indicate that this interaction is reciprocal, and that endo-
thelial cell survival factors can also modulate extracellular
matrix components, such as those in the endothelial glyco-
calyx. These observations do not preclude the possibility
that Ang1 is also affecting other aspects of endothelial cell
biology such as the density and activity of inter-endothelial
Figure 5 Angiopoietin-1 modiﬁes endothelial glycocalyx, but not inter-endothelial cleft ultrastructure. Inter-endothelial cleft and glycocalyx parameters were
measured at regular 50 nm intervals in electron micrographs prepared from vessels perfused with control solution, angiopoietin-1, pronase, or pronase exposure
in Ang1-perfused vessels. (A) Ang1 increased, and pronase decreased, glycocalyx depth. Ang1 perfusion did not alter glycocalyx depth in pronase-exposed
vessels. (B) Pronase exposure caused separation of the glycocalyx from the plasmalemma; Ang1 reversed this effect (*P , 0.05, one-way analysis of variance).
(C and D) There were no differences in the wide (C) or narrow (D) regions of inter-endothelial clefts between any experimental group. (E) Supernatant from
human microvascular endothelial cells, cultured in the presence of 200 ng mL
21 Ang1 or vehicle for 48 h, was added to Alcian Blue solution. Ang1 treatment
increased heparin sulphate equivalent (*P , 0.05, unpaired t-test). (F) The reduction in LP induced by Ang1 was abolished in the presence of the Golgi transloca-
tion inhibitor Brefeldin-A.
Ang1 alters glycocalyx and permeability coefﬁcients 31junction molecules, thereby making a parallel contribution
to the observed changes in microvascular barrier properties,
particularly in vessels with continuous endothelium.
Ang1 has heparin-binding/extracellular matrix-binding
properties,
40 and could modify the barrier properties
endowed by the endothelial glycocalyx by altering glycoca-
lyx biochemical structure. The receptors and downstream
signalling pathways responsible for this effect represent an
opportunity for further investigation. The time-course for
the Ang1-induced changes in glycocalyx effects (per-
meability coefﬁcients and glycocalyx thickness both
changed within 30 min of exposure) indicate that synthesis
of de novo glycocalyx constituents is unlikely to be respon-
sible. Ang1 is capable of altering the cell surface expression
of other molecules over a similar time-course (e.g. Tie2
40),
and microtubule-dependent trafﬁcking of heparan sulphate
has been observed in polarised renal epithelial cells.
41
Translocation of glycocalyx constituents from stores within
endothelial cells to the plasmalemma may therefore
explain the observed phenomena. We support this conten-
tion by demonstrating that inhibiting the translocation of
Golgi vesicles, which transport glycosaminoglycans (e.g.
hyaluronan
22) to the cell surface, inhibited the effect of
Ang1 on LP. Brefeldin-A disrupts translocation of cellular
material in minutes
39 and this is in keeping with our obser-
vations of altered LP and glycocalyx depth over this period.
The observations that Ang1 increased glycocalyx depth and
decreased LP accords with theoretical predictions that the
hydraulic resistance of the glycocalyx is determined by its
depth. However, a change in the molecular constitution or
arrangement of the glycocalyx is necessary to explain any
change in molecular sieving,
33 and Ang1 may therefore trans-
locate different glycocalyx constituents, or glycocalyx con-
stituents in different proportions, from those observed under
baseline conditions. Different effects of Ang1 on different
aspects of endothelial cell biology may occur in parallel (e.g.
restoration of continuity between glycocalyx and plasma-
lemma at the endothelial cell surface, and changes in inter-
endothelial cleft molecules), and may contribute tothe multi-
plicity of changes in permeability coefﬁcients observed in
different types of microvessels in these studies.
In summary, we show for the ﬁrst time that Ang1 alters
microvascular permeability coefﬁcients of intact microvessels
under baselineconditionsinvivo. Thisprovides a physiological
mechanism for previous reports that Ang1 alters transmural
ﬂux of solutes and tracers. We present anatomical, biochemi-
cal, and physiological evidence for Ang1-induced modiﬁcation
of a structure that is common to both continuous and fene-
strated endothelia—the endothelial glycocalyx—and suggest
that these modiﬁcations contribute to the Ang1-induced
changes in microvascular barrier function.
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